31 results about "Wedelolactone" patented technology

The invention provides a compound nano graphene oxide drug carrier, which is the drug carrier is used for combining a natural anti-neoplastic extract wedelolactone and a photosensitizer indocyanine green to the surface of the nano graphene oxide through Phi-Phi stacking interaction. A preparation method of the compound nano graphene oxide drug carrier comprises the following steps: graphene oxideis processed through an ultrasonic method, the nano graphene oxide is obtained, the Phi-Phi stacking interaction is used, and wedelolactone and indocyanine green are loaded on the surface of the nanographene oxide in order. The preparation method is simple, the particle size of the nano graphene oxide is controlled at 100-200 nm, cycle time of the drug carrier in body can be prolonged, the compound nano graphene oxide drug carrier can absorb 600-900 nm near infrared, luminous energy is transformed to heat energy, photo-thermal treatment is realized, under irradiation of 808 nm near infrared,active oxygen is generated, and a purpose of photodynamic therapy is realized.

The invention relates to a wedelolactone nanoliposome modified by combining chitosan and polyethylene glycol, which comprises long circulating liposome and a medicine active component wrapped in the long circulating liposome, the long circulating liposome is liposome modified by combining chitosan and polyethylene glycol on surface of liposome, the active component is wedelolactone, and wedelolactone is encapsulated between a bilaminar membrane of liposome. The preparation method of nanoliposome comprises the following steps: dissolving wedelolactone, soya lecithin and cholesterol in absolute ethyl alcohol, performing constant temperature magnetic stirring to obtain homogeneous oil phase, adding polyethylene glycol-2000 and chitosan in a hydration medium phosphoric acid buffer, performing constant temperature magnetic stirring to obtain the water phase; dropping the oil phase in the water phase to obtain a lipid suspension; removing absolute ethyl alcohol, and employing a cell ultrasonic pulverizer for performing interval ultrasound under ice bath. The preparation method can be carried out under normal temperature, normal pressure and mild condition, and has the advantages of simple technology and easy control, the obtained liposome has an ideal morphology, and the bioavailability is increased.

The invention relates to a drug application of a chemical substance wedelolactone for treatment of pulmonary fibrosis. The chemical substance wedelolactone is derived from a traditional Chinese medicine eclipta, and the structure is determined through spectral data; the wedelolactone can significantly improve the degree of model mouse lung tissue pulmonary fibrosis after intragastric administration, reduce NO (Nitrogen Oxide) and MDA (Methylene dioxyamphetamine) contents reflecting degree of lung injury, HYP (Hydroxyproline) content reflecting collagen deposition in the lung tissues, and cell factor TGF-beta 1 (Transforming Growth Factor) content causing pulmonary fibrosis, and inhibit human embryo lung fibroblast proliferation in vitro and HYP content of the human embryo lung fibroblast. In-vivo and in-vitro experiments show that wedelolactone can obviously improve bleomycin induced mouse pulmonary fibrosis, so that the wedelolactone can be taken as a novel drug for treating pulmonary fibrosis.

The invention relates to a new technology for large-scale preparation of a wedelolactone chemical reference substance. Through wedelolactone stability and preparation process streamlining optimization, a self-made large medium-pressure or pressure reduced silica gel column is employed for chromatography purification to obtain the wedelolactone chemical reference substance with purity greater than 98% in batches, and the scale is up to the 10g grade.

The invention relates to the field of medicines, in particular to an oral medicine composition for treating albinism. The oral medicine composition comprises medically acceptable excipients and raw materials. The raw materials include, by weight, 5-9 parts of wedelolactone and 1 part of metformin hydrochloride. The oral medicine composition has the advantages that obvious albinism treatment effects cannot be realized by the metformin hydrochloride, but albinism improving effects of the wedelolactone can be obviously improved if the metformin hydrochloride and the wedelolactone are jointly orally administered.

The invention relates to a method for extracting and separating wedelolactone from herba ecliptae. The method comprises the following steps: primary extraction, secondary extraction, tandem column separation and crystallization and is characterized by grinding a raw material herba ecliptae, carrying out extraction, carrying out tandem column separation and then carrying out crystallization, thus obtaining required wedelolactone. The method for extracting wedelolactone from the raw material herba ecliptae is simple to operate, has the advantages of high product content and high recovery rate and is suitable for industrial production.

The invention discloses a method for preparing wedelolactone monomeric compounds extracted and purified from a traditional Chinese medicine eclipta. The method comprises the following steps: grinding the eclipta into powder, adding an alcohol-acid aqueous solution for performing multistage counter-current extraction, filtering the extracting solution, and performing vacuum concentration, thereby obtaining a coarse product of wedelolactone; separating and purifying by virtue of a macroporous resin, performing gradient elute, collecting the eluent, and respectively performing vacuum concentration, thereby respectively obtaining wedelolactone and demethylwedelolactone. By utilizing good and stable physico-chemical properties of wedelolactone compounds under weak acid conditions, the active ingredients of the eclipta are protected in the process of extracting by using the alcohol-acid aqueous solution, the extraction rate of the active ingredients in the eclipta medicinal materials is greatly improved, the macroporous resin can be repeatedly utilized, an ethanol aqueous solution serves as a solvent and is economical and practical, high-purity wedelolactone and demethylwedelolactone compounds can be conveniently and efficiently obtained, the purity of each monomeric compound is over 95 percent, and the method is simple in process, easy and convenient to operate, low in cost and suitable for batch production.

The invention relates to a molecular traditional Chinese medicine sustained-release tablet for resisting bone mass loss and a preparation method thereof. The molecular traditional Chinese medicine sustained-release tablet comprises molecular traditional Chinese medicine ingredients and pharmaceutically allowed auxiliary material ingredients, wherein the molecular traditional Chinese medicine components comprise 1-5 parts of specnuezhenide (ligustrum lucidum), 1-5 parts of wedelolactone (eclipta prostrata), 0.5-3 parts of paeoniflorin (peony), 0.5-3 parts of psoralen (psoralea corylifolia), and 1-5 parts of diosgenin (yam) ]; and the auxiliary material ingredients comprise 10-50 parts of sodium alginate, 1-5 parts of carbomer (934) , 10-30 parts of hydroxypropyl methyl cellulose, 10-40 parts of lactose, and 1-5 parts of magnesium stearate. Based on a theory of Chinese medicine and a theory of sustained-release preparations, Chinese medicine pathological features of postmenopausal osteoporosis, and scientific compatibility, the molecular traditional Chinese medicine sustained-release tablet which is safe and reliable, high in bioavailability and significant in curative effect is developed.